Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR

Affiliation auteurs!!!! Error affiliation !!!!
TitrePazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR
Type de publicationJournal Article
Year of Publication2016
AuteursGuigay J., Bidault F., Fayette J., Even C., Cupissol D., Rolland F., Peyrade F., Laguerre B., Le Tourneau C., Zanetta S., L. Le Moal B, Borel C., Digue L., Delaye J., Diffetocq S., Costes V., Auperin A., Faivre L.
JournalANNALS OF ONCOLOGY
Volume27
Date PublishedOCT 1
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1093/annonc/mdw376.38